Gilead Sciences ((GILD)), Arcus Biosciences ((RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The clinical study titled ‘A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)’ aims to assess the safety and preliminary clinical activity of various treatment combinations, with and without chemotherapy, in patients with advanced gastric, GEJ, and esophageal adenocarcinoma. This study is significant as it explores potential new treatment options for these challenging cancers.
The interventions being tested include a combination of drugs such as Domvanalimab, Zimberelimab, Quemliclustat, and the chemotherapy regimen FOLFOX, which includes Fluorouracil, Leucovorin, and Oxaliplatin. These treatments are designed to target cancer cells more effectively, potentially improving patient outcomes.
The study follows a randomized, parallel intervention model with no masking, focusing primarily on treatment. This design allows for a clear comparison of the safety and efficacy of the different treatment combinations.
The study began on June 10, 2022, with an active, not recruiting status as of the last update on August 7, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
The update could influence the stock performance of Gilead Sciences and Arcus Biosciences by boosting investor confidence if the results are positive. The study’s progress also positions these companies competitively within the oncology sector, potentially impacting their market standing.
The study is ongoing, with further details available on the ClinicalTrials portal.